Schrödinger (software)

Schrödinger (software)
Name	Schrödinger
Developer	Schrödinger, Inc.
Released	1990s
Latest release	(proprietary)
Operating system	Microsoft Windows; macOS; Linux
Genre	Computational chemistry; molecular modeling; cheminformatics
License	Commercial

Schrödinger (software) is a proprietary suite of computational chemistry and molecular modeling tools produced by Schrödinger, Inc., designed for structure-based drug design, virtual screening, and materials modeling. The package integrates quantum chemistry, molecular mechanics, and cheminformatics engines with graphical interfaces and workflow automation to support projects in pharmaceuticals, biotechnology, and academia. The platform has been used in collaborations with companies and institutions such as Pfizer, Novartis, GlaxoSmithKline, Merck & Co., and universities including Harvard University, Stanford University, Massachusetts Institute of Technology, and University of Cambridge.

Overview

The suite combines algorithms for molecular docking, molecular dynamics, ligand preparation, and property prediction, interoperating with third-party packages and standards from organizations such as OpenEye Scientific, Chemical Abstracts Service, InChI Trust, and Protein Data Bank. Core components implement force fields and quantum methods compatible with models from AMBER, OPLS, and methodologies developed in literature by groups affiliated with Columbia University, University of California, San Francisco, and Yale University. The software supports integration with laboratory informatics systems used by firms like AstraZeneca and Bayer and workflows common to projects associated with grant programs from agencies such as the National Institutes of Health, European Research Council, and Wellcome Trust.

History and Development

Development began in the 1990s amid advances in computational chemistry pioneered at institutions like Bell Labs, Brookhaven National Laboratory, and Lawrence Berkeley National Laboratory. Founders of Schrödinger, Inc. built on algorithms and implementations influenced by work from investigators at Columbia University and collaborations with groups at Memorial Sloan Kettering Cancer Center. Over successive releases the company added capabilities for quantum mechanical calculations inspired by methods from John Pople's legacy and dense-matrix approaches used in projects at Los Alamos National Laboratory. Strategic partnerships and corporate collaborations included ties with Iconix Pharmaceuticals and research consortia funded by DARPA and national research councils in the United Kingdom and Germany.

Features and Modules

The platform offers modules for ligand preparation, receptor preparation, docking, free-energy perturbation, and molecular dynamics, often invoked in pipelines alongside applications from Schrodinger, Inc. (company-wide branding). Key modules include ligand pre-processing tools analogous to utilities from Open Babel and docking engines comparable to methods from groups at Scripps Research, while quantum mechanics modules reflect approaches from Gaussian (software) authors and implementations parallel to NWChem and Q-Chem. Free-energy calculations leverage protocols similar to those developed in studies at University of California, San Diego and Harvard Medical School. Visualization and GUI elements draw inspiration from interfaces used by PyMOL and ChimeraX.

Applications in Computational Chemistry and Drug Design

Researchers apply the suite in lead identification, lead optimization, binding affinity prediction, and ADMET profiling in projects undertaken by corporations like Eli Lilly and Company and laboratories at Johns Hopkins University and California Institute of Technology. Notable applications include virtual screening campaigns comparable to those published by teams at Broad Institute and free-energy-driven optimization reported in collaborations with Genentech and academic groups at University of Toronto. The software has also been used in materials modeling projects tied to research at Argonne National Laboratory and Oak Ridge National Laboratory.

Licensing and Distribution

The product is distributed under commercial licenses to pharmaceutical companies, biotech firms, and academic institutions, with licensing models similar to enterprise agreements seen at IBM and Microsoft. Academic licensing options have enabled university groups at Imperial College London and University College London to access research licenses, while industry collaborations resemble partnerships common to firms like Schrödinger, Inc. and contract research organizations including Charles River Laboratories.

Reception and Criticism

Peer-reviewed assessments in journals and comparisons conducted by groups at Princeton University, University of California, Berkeley, and ETH Zurich have highlighted strong performance in structure-based design and free-energy predictions while noting limitations typical of continuum-solvent models and force-field accuracy issues debated in literature from Royal Society of Chemistry and conferences organized by the American Chemical Society. Criticisms cited by practitioners at GSK and independent investigators include the cost of licenses and the need for careful parametrization when modeling novel chemotypes, echoing discussions at symposia hosted by Gordon Research Conferences and workshops at EMBL.

Category:Computational chemistry software